Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIb, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Efficacy and Safety of Dirocaftor/Posenacaftor/Nesolicaftor in Subjects With Cystic Fibrosis Aged 18 Years or Older

NCT06468527 is registered in ClinicalTrials.gov with Kors van der Ent as lead sponsor.

NCT NCT06468527
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06468527 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIb, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Efficacy and Safety of Dirocaftor/Posenacaftor/Nesolicaftor in Subjects With Cystic Fibrosis Aged 18 Years or Older
Lead sponsor
Kors van der Ent
Phase
Phase 2
Overall status
Completed
Start date
June 3, 2024
Completion date
June 26, 2025
Enrollment
41 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

cystic fibrosis